Man Group
OVID icon

Man Group’s Ovid Therapeutics OVID Stock Holding History

Man Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– – – 1991
2022
Q2 		– Sell
-47,863
Closed -$150K – 2320
2022
Q1 		$150K Buy
+47,863
New +$151K ﹤0.01% 1999

Other funds holding OVID

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Man Group's OVID Position: Q1 2023 in Review

Man Group held its Ovid Therapeutics (OVID) position steady in Q1 2023 at 0 shares worth $71.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

Man Group first reported a position in OVID in Q1 2022 and has held it in 1 quarter since. The position peaked at $150K in Q1 2022. 60 funds tracked by Wall St. Rank hold OVID as of Q1 2023.

  • Man Group held 0 shares of Ovid Therapeutics worth $71.6K as of Q1 2023.
  • Man Group left its Ovid Therapeutics share count unchanged in Q1 2023.
  • Ovid Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2023, its #1991 holding.
  • Man Group first reported a position in Ovid Therapeutics in Q1 2022 and has held it in 1 quarter since.
  • Man Group's Ovid Therapeutics position peaked at $150K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.